多晶硅主力合約持續拉昇，現漲超3%，報34070元/噸。

Domestic equity private funds raised exposure for four consecutive weeks from June 26, lifting average equity positions by 2.12 percentage points to 84.12% as of July 24 — a 4+-year high (last above 84.12% was 84.30% on April 1, 2022). Funds holding >80% positions now account for 70.43% of equity private funds. Equity private funds with ≥¥10bn AUM averaged 88.64% as of July 24, the highest level year-to-date and the top among size cohorts.

Financial Times: AstraZeneca is exploring a merger with U.S. peer Bristol Myers Squibb that would create one of the world’s largest drugmakers with a combined market value near $400 bln. The companies have held talks in recent months and could reach an agreement soon, but negotiations may also be delayed or collapse. AstraZeneca’s market cap is about £196 bln; Bristol Myers Squibb’s is about $133 bln. The transaction would further accelerate AstraZeneca’s strategic shift toward the U.S. market.